second pivotal Phase III trial initiated 6/06; anticipated marketing approval 2010; completed Phase II trial for Huntington's disease 7/08; positive Phase III results for mild to moderate Alzheimer's disease 7/08; also being studied in Phase III in combination with donepezil; animal research presented at ICAD showed increase of beta-amyloid levels (a chemical experts believe to be a "culprit" in the disease)7/09; phase III initiated for Huntington's disease 7/09; two phase III trials initiated in moderate-to-severe Alzheimers 11/09; positive phase III data for Alzheimers (2/10); drug failed to meet either primary or secondary endpoints vs placebo (3/10)
Brand Dimebon Generic latrepirdine
Company name Medivation, Pfizer Product type Non-speciality
Therapeutic category CNS Key uses Alzheimer's Disease, Huntington disease
Other Uses N/A Drug Class inhibit brain cell death
Dosage From oral Expected Approval 2012+
FDA Filing N/A Last Update date June 02,2010
Link to pipeline report
Link to news article
Link to clinicaltrials.gov